PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions

AbCellera Biologics Inc. (ABCL)

Equity · Currency in USD · Last updated Dec 2, 2023
SummaryFinancials

Company Info

ISINCA00288U1066
CUSIP00288U106
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$1.36B
EPS-$0.44
Revenue (TTM)$50.39M
Gross Profit (TTM)$311.11M
EBITDA (TTM)-$178.29M
Year Range$3.87 - $12.72
Target Price$22.00
Short %13.18%
Short Ratio18.73

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in AbCellera Biologics Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%20.00%JulyAugustSeptemberOctoberNovemberDecember
-91.80%
25.42%
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ABCL

AbCellera Biologics Inc.

Return

AbCellera Biologics Inc. had a return of -52.32% year-to-date (YTD) and -63.35% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-52.32%19.67%
1 month17.23%8.42%
6 months-28.87%7.29%
1 year-63.35%12.71%
5 years (annualized)N/A10.75%
10 years (annualized)N/A9.87%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20232.80%-7.32%19.66%-29.50%-15.60%-10.65%14.60%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for AbCellera Biologics Inc. (ABCL) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ABCL
AbCellera Biologics Inc.
-1.18
^GSPC
S&P 500
0.91

Sharpe Ratio

The current AbCellera Biologics Inc. Sharpe ratio is -1.18. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00JulyAugustSeptemberOctoberNovemberDecember
-1.18
0.91
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

Dividend History


AbCellera Biologics Inc. doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-91.80%
-4.21%
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the AbCellera Biologics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AbCellera Biologics Inc. was 93.36%, occurring on Oct 27, 2023. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-93.36%Dec 14, 2020723Oct 27, 2023

Volatility Chart

The current AbCellera Biologics Inc. volatility is 17.74%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%20.00%JulyAugustSeptemberOctoberNovemberDecember
17.74%
2.79%
ABCL (AbCellera Biologics Inc.)
Benchmark (^GSPC)